Deciphering the rule of antigen-antibody amino acid interaction

Front Immunol. 2023 Dec 4:14:1269916. doi: 10.3389/fimmu.2023.1269916. eCollection 2023.

Abstract

Purpose: Antigenic drift is the biggest challenge for mutagenic RNA virus vaccine development. The primary purpose is to determine the IEMM (immune escape mutation map) of 20 amino acids' replacement to reveal the rule of the viral immune escape.

Methods: To determine the relationship between epitope mutation and immune escape, we use universal protein tags as a linear epitope model. To describe and draw amino acid linkage diagrams, mutations of protein tags are classified into four categories: IEM (immune escape mutation), ADERM (antibody-dependent enhancement risk mutation), EQM (equivalent mutation), and IVM (invalid mutation). To overcome the data limitation, a general antigen-antibody (Ag-Ab) interaction map was constructed by analyzing the published three-dimensional (3D) Ag-Ab interaction patterns.

Results: (i) One residue interacts with multiple amino acids in antigen-antibody interaction. (ii) Most amino acid replacements are IVM and EQM. (iii) Once aromatic amino acids replace non-aromatic amino acids, the mutation is often IEM. (iv) Substituting residues with the same physical and chemical properties easily leads to IVM. Therefore, this study has important theoretical significance for future research on antigenic drift, antibody rescue, and vaccine renewal design.

Conclusion: The antigenic epitope mutations were typed into IEM, ADERM, EQM, and IVM types to describe and quantify the results of antigenic mutations. The antigen-antibody interaction rule was summarized as a one-to-many interaction rule. To sum up, the epitope mutation rules were defined as IVM and EQM predomination rules and the aryl mutation escape rule.

Keywords: antibody; antigen; antigenic drift; interaction; reverse antibody technique.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids* / genetics
  • Antibodies, Viral
  • Epitopes
  • Hemagglutinin Glycoproteins, Influenza Virus*
  • Mutation

Substances

  • Hemagglutinin Glycoproteins, Influenza Virus
  • Amino Acids
  • Antibodies, Viral
  • Epitopes

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The research was funded by a research grant from the National Natural Science Foundation of China (30972585). Guangdong Key Laboratory funds of Systems Biology and Synthetic Biology for Urogenital Tumors (2017B030301015) and its Open Grant (2021B030301015-2).